Filtros de búsqueda

Lista de obras de Jonathan Cebon

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response

scientific article published on 30 September 2019

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265).

artículo científico publicado en 2015

A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.

artículo científico publicado en 2012

A comprehensive promoter landscape identifies a novel promoter for CD133 in restricted tissues, cancers, and stem cells.

artículo científico publicado en 2013

A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.

artículo científico publicado en 2012

A novel method for detecting antigen-specific human regulatory T cells

artículo científico publicado en 2012

A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours ⬇️

artículo científico publicado el 1 de mayo de 2003

A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake

artículo científico publicado en 2005

A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant

artículo científico publicado en 2017

A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme

artículo científico publicado en 2014

Advance care planning in patients with incurable cancer: study protocol for a randomised controlled trial

artículo científico publicado en 2016

Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity.

artículo científico publicado en 2016

Alternate antigen processing in the presence of gamma interferon may misdirect the immune recognition of cancer.

artículo científico publicado en 2015

Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature

artículo científico publicado en 2019

Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy

artículo científico publicado en 2018

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.

artículo científico publicado en 2018

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

artículo científico publicado en 2019

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

artículo científico publicado en 2013

Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma

artículo científico publicado en 2021

Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells

artículo científico publicado en 2020

CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients

artículo científico publicado en 2002

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

artículo científico publicado en 2017

CT-X antigen expression in human breast cancer.

artículo científico publicado en 2009

Cancer stem cells in urologic cancers.

artículo científico publicado en 2009

Cancer vaccines: Where are we going?

artículo científico publicado en 2010

Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells.

artículo científico publicado en 2009

Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forces

artículo científico publicado en 2016

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma

artículo científico publicado en 2015

Characterising the phenotypic evolution of circulating tumour cells during treatment.

artículo científico publicado en 2018

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

artículo científico publicado en 2014

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.

artículo científico publicado en 2009

Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma

artículo científico publicado en 2014

Clinicopathological characteristics associated with BRAF(K601E) and BRAF(L597) mutations in melanoma

artículo científico publicado en 2015

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

artículo científico publicado en 2014

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

artículo científico publicado en 2012

Correction: Frequent MAGE Mutations in Human Melanoma.

artículo científico publicado en 2010

Cytokine regulation of colony-stimulating factor (CSF) production in cultured human synovial fibroblasts. II. Similarities and differences in the control of interleukin-1 induction of granulocyte-macrophage CSF and granulocyte-CSF production ⬇️

artículo científico publicado el 15 de marzo de 1992

Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor ⬇️

artículo científico publicado el 15 de noviembre de 1990

Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy.

artículo científico publicado en 2018

Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens.

artículo científico publicado en 2014

Directed evolution for improved secretion of cancer-testis antigen NY-ESO-1 from yeast

artículo científico publicado en 2006

Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.

artículo científico publicado en 2006

Distinctive subpopulations of stromal cells are present in human lymph nodes infiltrated with melanoma

artículo científico publicado en 2020

Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide.

artículo científico publicado en 2018

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program

scientific article published on 01 October 2019

Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells

artículo científico publicado en 2014

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

artículo científico publicado en 2016

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

artículo científico publicado en 2017

Embryonic Chicken Transplantation is a Promising Model for Studying the Invasive Behavior of Melanoma Cells

artículo científico publicado en 2015

Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.

artículo científico publicado en 2010

Evolving role of tumor antigens for future melanoma therapies.

artículo científico publicado en 2014

Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma ⬇️

artículo científico publicado el 20 de diciembre de 2011

FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis

artículo científico publicado en 2014

Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein.

artículo científico publicado en 2013

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.

artículo científico

Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects.

artículo científico publicado en 2012

Frequent MAGE Mutations in Human Melanoma ⬇️

artículo científico publicado el 16 de septiembre de 2010

Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel

scientific article published on 05 February 2019

Hepatocellular carcinoma and chemoembolization ⬇️

artículo científico publicado el 1 de diciembre de 2001

Human articular cartilage and chondrocytes produce hemopoietic colony-stimulating factors in culture in response to IL-1 ⬇️

artículo científico publicado el 15 de agosto de 1991

Human perforin mutations and susceptibility to multiple primary cancers

artículo científico publicado en 2013

IL-1β Enhances CD40 Ligand-Mediated Cytokine Secretion by Human Dendritic Cells (DC): A Mechanism for T Cell-Independent DC Activation ⬇️

artículo científico publicado el 15 de enero de 2002

Identifying and targeting determinants of melanoma cellular invasion.

artículo científico publicado en 2016

Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.

artículo científico publicado en 2014

Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.

artículo científico publicado en 2011

Immunotherapy of Ipilimumab and Nivolumab in patients with advanced neuroendocrine tumours: a subgroup analysis of the CA209-538 clinical trial for rare cancers

artículo científico publicado en 2020

Increased tolerance to endotoxin by granulocyte-macrophage colony-stimulating factor-deficient mice ⬇️

artículo científico publicado el 1 de agosto de 1997

Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy ⬇️

artículo científico publicado el 26 de agosto de 2012

Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle-Associated PDGFRβ.

artículo científico publicado en 2017

Interleukin-4 suppresses granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in stimulated human monocytes ⬇️

artículo científico publicado el 1 de agosto de 1992

Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors

artículo científico publicado en 2013

Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules

article published in the Proceedings of the National Academy of Sciences of the United States of America

Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations.

artículo científico publicado en 2016

Long-Term Follow-Up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients With Advanced Melanoma: KEYNOTE-029 Part 1B

scientific article published on 30 June 2020

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

artículo científico publicado en 2017

Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma

article

MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.

artículo científico publicado en 2014

MEK inhibition, alone or in combination with BRAF inhibition, impairs multiple functions of isolated normal human lymphocytes and dendritic cells.

artículo científico publicado en 2013

Mapping the distinctive populations of lymphatic endothelial cells in different zones of human lymph nodes

artículo científico publicado en 2014

Measurement and clinical significance of circulating hematopoietic growth factor levels

artículo científico publicado el 1 de mayo de 1994

Melanoma vaccines: developments over the past 10 years.

artículo científico publicado en 2011

Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma.

artículo científico publicado en 2016

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.

artículo científico publicado en 2015

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma

artículo científico publicado en 2018

Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro

artículo científico publicado en 2015

NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus

artículo científico publicado en 2014

Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma

scientific article published on 09 September 2018

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

artículo científico publicado en 2018

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

artículo científico publicado en 2017

Optimal effector functions in human natural killer cells rely upon autocrine bone morphogenetic protein signaling

artículo científico publicado en 2014

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.

artículo científico publicado en 2016

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

artículo científico publicado en 2016

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

artículo científico publicado en 2017

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

artículo científico publicado en 2017

Perspective: cancer vaccines in the era of immune checkpoint blockade

artículo científico publicado en 2018

Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer ⬇️

artículo científico publicado el 1 de junio de 1998

Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma

artículo científico publicado en 2017

Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies

artículo científico publicado el 1 de julio de 1994

Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma

artículo científico publicado en 2015

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

artículo científico publicado en 2017

Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion

artículo científico publicado en 2015

Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor ⬇️

artículo científico publicado el 1 de mayo de 1998

Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma

artículo científico publicado en 2018

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis

artículo científico publicado en 2011

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

artículo científico publicado en 2004

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

artículo científico publicado en 2017

Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.

artículo científico publicado en 2014

Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP.

artículo científico publicado en 2016

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

artículo científico publicado en 2020

Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series

scientific article published on 13 November 2018

Sentinel node biopsy for melanoma: The medical oncology perspective

Somatostatin receptor expression, tumour response and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.

artículo científico publicado en 2007

Sphingosine-1-phosphate lyase is expressed by CD68+cells on the parenchymal side of marginal reticular cells in human lymph nodes

artículo científico publicado en 2014

Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma

scientific article published on 16 September 2020

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

artículo científico

Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1.

artículo científico publicado en 2006

Systems analysis identifies miR-29b regulation of invasiveness in melanoma.

artículo científico publicado en 2016

The Ets transcription factor ELF5 functions as a tumor suppressor in the kidney.

artículo científico publicado en 2011

The dissociation of GM-CSF efficacy from toxicity according to route of administration: a pharmacodynamic study

artículo científico publicado el 1 de febrero de 1992

The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.

artículo científico publicado en 2014

The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.

artículo científico publicado en 2013

The role of circulating microRNA in hepatocellular carcinoma.

artículo científico publicado en 2015

Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma

artículo científico publicado en 2014

Towards improved cancer therapy using subcutaneously administered hemopoietic colony stimulating factors

artículo científico publicado el 1 de enero de 1990

Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma

artículo científico publicado en 2020

Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells.

artículo científico publicado en 2016

Tumor-specific T-cell help is associated with improved survival in melanoma.

artículo científico publicado en 2013

Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes.

artículo científico publicado en 2015

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy

artículo científico publicado en 2015

Viability and Quantification of Progenitor Cells in Venesected Blood from Patients Receiving Escalated-Dose Epirubicin and Cyclophosphamide with G-CSF for Lymphoma: Potential Role in Further Increasing Dose-Intensity ⬇️

artículo científico publicado el 1 de octubre de 1997

Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma

artículo científico publicado en 2015

Whole-genome landscapes of major melanoma subtypes.

artículo científico publicado en 2017

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda